Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras.
about
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylationModulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoproteinHPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytesNonradioactive RNA in situ hybridization detection of human papillomavirus 16-E7 transcripts in squamous cell carcinomas of the uterine cervix using confocal laser scan microscopy.DNA vaccines for cervical cancerCounseling the patient with potentially HPV-related newly diagnosed head and neck cancerLaboratory techniques in the investigation of human papillomavirus infection.Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens.Cell-mediated immune response to human papillomavirus infection.Carrageenan as an adjuvant to enhance peptide-based vaccine potencyConstitutive expression of c-myc oncogene confers hormone independence and enhanced growth-factor responsiveness on cells transformed by human papilloma virus type 16.Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activationA synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies.DNA vaccines for cervical cancer: from bench to bedside.Molecular events in uterine cervical cancer.Detection of human papillomavirus type 18 E7 oncoprotein in cervical smears: a feasibility study.Delineation of human papillomavirus type 18 enhancer binding proteins: the intracellular distribution of a novel octamer binding protein p92 is cell cycle regulated.The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses.Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cellsSequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation.Human papillomavirus and head and neck squamous cell carcinoma: recent evidence and clinical implicationsClinical implications of human papillomavirus in head and neck cancers.Metastatic conversion of cells by expression of human papillomavirus type 16 E6 and E7 genes.Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids.Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HeLa X fibroblast hybrid cells.Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells.Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications.Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16A point mutational analysis of human papillomavirus type 16 E7 protein.Human papillomaviruses and cervical neoplasia. I. Classification, virology, pathology, and epidemiology.Human papillomaviruses and cervical neoplasia. II. Interaction of HPV with other factors.Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen.A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes.Degenerate cysteine patterns mediate two redox sensing mechanisms in the papillomavirus E7 oncoprotein.Papilloma formation by cottontail rabbit papillomavirus requires E1 and E2 regulatory genes in addition to E6 and E7 transforming genes.Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons.Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression.Human papillomavirus type 18 E6*, E6, and E7 protein synthesis in cell-free translation systems and comparison of E6 and E7 in vitro translation products to proteins immunoprecipitated from human epithelial cells.Repression of the human papillomavirus type 18 enhancer by the cellular transcription factor Oct-1.Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16.
P2860
Q24300757-0CA0DDD4-0B2D-4B63-83C9-036C59731B4EQ24676090-A315F305-91C0-4BF3-BF4C-D0688467E694Q28254780-1E2085D8-2702-43A4-96D2-A28B275C789AQ33267990-6B1D807A-DB68-4F4C-ACD0-FA36A40FE2DBQ33680693-32C4809F-545C-428C-8658-90BDDAE4139FQ33908473-8150E3D5-9A83-4A28-B1CD-D5DD1EC7C1B2Q33933492-56BC81AA-C486-4C5D-9F68-CB2B03EE1AA4Q33938457-8A1F350F-7829-4B9D-9961-288F99EC9B2DQ33998922-F6602E51-6B34-46FF-92D6-F0AA23307E13Q34012257-36ECB319-9EAD-40CD-AB9F-F1860439D9E1Q34293682-2B787DD5-F718-4546-961A-1E542DE1D805Q34397856-DD76C5DE-5773-4CDB-AB9E-C298C7FCF7F6Q34858337-8EF8D068-25CD-4528-B155-C36E327EAC5FQ35234992-762299D1-4386-4673-A32D-C5D0D7A3C4A8Q35562096-446CA336-61DB-4B0E-9A76-39F09251BF93Q35689066-5ECE59E7-1757-48A1-87D4-6CB9A49ABC4FQ35804675-E831E342-2765-484E-92B5-C435BF245A44Q35838573-B93443B9-6CB1-467C-90E2-7268F50E3602Q35838905-1B623B9B-0274-4526-B188-41EF7FF241A3Q35848569-2CC9A4D4-BC76-4798-86AB-4764D56F2734Q35866493-4F722639-F204-44D3-9B1B-3AAB37F8B4B6Q36416436-8EA80D4B-13DE-4E39-9F00-FDC6606CB60AQ36417356-A80B2323-67E8-47A1-84B3-2C8C37AA688EQ36631278-613BF3E7-0F47-4EE8-8E2D-3FA645870739Q36783824-5CC45B9A-45B8-4767-BB38-4AD63FDE553FQ36783874-BC889554-E3E4-44E7-821B-8F21ACB51909Q36795668-74439304-2C64-4BF0-84A7-08868C17A24FQ36797645-98ECE029-B733-4367-9590-1E19017AE8ACQ36828310-413CE2FB-28A2-44D6-819A-426E705C0F04Q37254122-E0EB17A6-3C93-4A98-92FE-8F7DCF071D4FQ37255166-727403C0-2E45-47B2-B7C3-5FCF67ECB13DQ37360322-2977AB24-D4BA-46D8-91AB-2030058F8286Q37542899-A78DF40A-39A3-461A-A8A5-D8D0FB51AD35Q37611952-29A54346-5591-4410-A4A5-2485CD534C64Q40041685-4222B71D-6876-4773-AE63-FB9D392DA2B6Q40045388-0DA5782F-EA84-487F-8A56-6CE12625C9ABQ40062749-3AE5EDCE-F0D0-4426-90E9-EFBE196771DFQ40106854-62BEA1EA-1BD9-49ED-964C-DA857450A5ADQ40107396-8C47003C-43A5-4096-8E83-5F7F3CED6820Q40505725-93CD4FF4-4503-486B-B62A-DE03A7A7D987
P2860
Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras.
description
1989 nî lūn-bûn
@nan
1989 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Continued expression of HPV-16 ...... sformed by HPV-16 plus EJ-ras.
@ast
Continued expression of HPV-16 ...... sformed by HPV-16 plus EJ-ras.
@en
Continued expression of HPV-16 ...... sformed by HPV-16 plus EJ-ras.
@nl
type
label
Continued expression of HPV-16 ...... sformed by HPV-16 plus EJ-ras.
@ast
Continued expression of HPV-16 ...... sformed by HPV-16 plus EJ-ras.
@en
Continued expression of HPV-16 ...... sformed by HPV-16 plus EJ-ras.
@nl
prefLabel
Continued expression of HPV-16 ...... sformed by HPV-16 plus EJ-ras.
@ast
Continued expression of HPV-16 ...... sformed by HPV-16 plus EJ-ras.
@en
Continued expression of HPV-16 ...... sformed by HPV-16 plus EJ-ras.
@nl
P2093
P2860
P1433
P1476
Continued expression of HPV-16 ...... nsformed by HPV-16 plus EJ-ras
@en
P2093
P2860
P304
P356
10.1002/J.1460-2075.1989.TB03405.X
P407
P577
1989-02-01T00:00:00Z